# Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia

> **NCT06223919** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Universidad Nacional de Colombia** · enrollment: 8686 (estimated)

## Conditions studied

- Monkeypox

## Interventions

- **BIOLOGICAL:** LC16m8

## Key facts

- **NCT ID:** NCT06223919
- **Lead sponsor:** Universidad Nacional de Colombia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-16
- **Primary completion:** 2024-08-20
- **Final completion:** 2025-12
- **Target enrollment:** 8686 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223919, "Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06223919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*